NasdaqGM - Delayed Quote USD

Aurinia Pharmaceuticals Inc. (AUPH)

4.8100 -0.1000 (-2.04%)
At close: April 18 at 4:00 PM EDT
4.8000 -0.01 (-0.21%)
After hours: April 18 at 5:27 PM EDT
Loading Chart for AUPH
DELL
  • Previous Close 4.9100
  • Open 4.9000
  • Bid 4.8100 x 200
  • Ask 4.8300 x 500
  • Day's Range 4.7100 - 4.9550
  • 52 Week Range 4.7100 - 12.4300
  • Volume 2,047,478
  • Avg. Volume 2,119,498
  • Market Cap (intraday) 695.613M
  • Beta (5Y Monthly) 1.38
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5400
  • Earnings Date May 2, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.29

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

www.auriniapharma.com

300

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AUPH

Performance Overview: AUPH

Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AUPH
46.50%
S&P 500
5.06%

1-Year Return

AUPH
55.30%
S&P 500
20.71%

3-Year Return

AUPH
61.05%
S&P 500
19.73%

5-Year Return

AUPH
23.89%
S&P 500
72.77%

Compare To: AUPH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AUPH

Valuation Measures

As of 4/18/2024
  • Market Cap

    695.61M

  • Enterprise Value

    442.73M

  • Trailing P/E

    --

  • Forward P/E

    121.95

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.93

  • Price/Book (mrq)

    1.84

  • Enterprise Value/Revenue

    2.52

  • Enterprise Value/EBITDA

    -7.02

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -44.45%

  • Return on Assets (ttm)

    -10.52%

  • Return on Equity (ttm)

    -19.92%

  • Revenue (ttm)

    175.51M

  • Net Income Avi to Common (ttm)

    -78.02M

  • Diluted EPS (ttm)

    -0.5400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    350.37M

  • Total Debt/Equity (mrq)

    25.82%

  • Levered Free Cash Flow (ttm)

    -3.89M

Research Analysis: AUPH

Analyst Price Targets

8.00
11.29 Average
4.8100 Current
15.00 High
 

Fair Value

Overvalued
% Return
4.8100 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Research Reports: AUPH

  • Daily – Vickers Top Insider Picks for 08/11/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 08/10/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 08/09/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 08/06/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     

People Also Watch